CLEVELAND, Feb. 14, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today details relating to the release of
its fourth quarter and full year 2018 financial results.
ViewRay will hold a conference call to discuss results on
Thursday March 14, 2019 at
4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844)
277-1426 for domestic callers and (336) 525-7129 for international
callers. The conference ID number is 7659688. A live webcast of the
conference call will be available on the investor relations page of
ViewRay's corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain
available online on the investor relations page of ViewRay's
corporate website, www.viewray.com, for 14 days following the call.
In addition, a telephonic replay of the call will be available
until March 21, 2019. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. Please use the conference ID
number 7659688.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY),
designs, manufactures and markets the MRIdian® radiation therapy
system. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology.
Unlike MR systems used in diagnostic radiology, MRIdian's
high-definition MR was purpose built to address specific
challenges, including beam distortion, skin toxicity, and other
concerns that potentially may arise when high magnetic fields
interact with radiation beams. ViewRay and MRIdian are registered
trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These statements are subject to risks and uncertainties
that could cause future results to differ materially from those
referenced. Forward looking statements include, but are not limited
to references to the recent study results, clinical trial results,
related clinical experience and patient outcomes. Given these
uncertainties, the reader is advised not to place any undue
reliance on any forward-looking statements. Additional risk factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates, government and regulatory
uncertainty, including but not limited to obtaining authorizations
to market and new tariffs and trade restrictions, and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available
at www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-and-webcast-of-fourth-quarter-and-full-year-2018-financial-results-to-be-held-after-market-on-march-14-2019-300795547.html
SOURCE ViewRay, Inc.